HEAT PPCI published by The Lancet
A major study has been published by The Lancet claiming that routine use of heparin rather than bivalirudin could improve outcomes for heart attack patients, while at the same time significantly reducing costs for healthcare organisations globally.
Researchers at LHCH conducted what they believe to be the largest single-centre trial (HEAT-PPCI) ever undertaken in cardiovascular medicine.
The study was also exceptional in that it recruited all patients presenting with a heart attack event, to create a population that reflects everyday clinical reality. Of the 1829 participants the oldest was 102 and the youngest 21; patients had home addresses on four continents.
The optimum treatment of a heart attack event is an emergency angioplasty and stent procedure, to re-open a blocked heart artery. This 22 month research trial compared the performance of two drugs, heparin and bivalirudin used as anticlotting agents in this setting.
The research findings were presented at the American College of Cardiology 63rd Annual Scientific Session & Expo in Washington DC in March.
The results suggest that, when compared to bivalirudin:
- use of heparin was associated with a substantial reduction in the incidence of early recurrent heart attack
- use of heparin was also associated with marginally fewer deaths and strokes
- use of heparin would prevent three serious adverse events for every hundred patients treated.